Open Orphan (ORPH) Chief Executive Officer, Cathal Friel discuss an operational update on the Vox Markets Podcast with Justin Waite July 15, 2019 – Posted in: Open Orphan (ORPH) – Tags: drug discovery, European clinical research organisation, european rare disease programmes, Open Orphan, rare and orphan drug consulting services platform., targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Click here to listen to the interview
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.